No Data
Hejing Biotech: Beijing Hejing Biotechnology Co., Ltd. 2024 Annual Performance Report Announcement
Beijing Hejing Biotechnology Co., Ltd. 2024 Annual Performance Report Announcement
Beijing Hotgen Biotech Co.,Ltd (688068.SH): Net loss of 86.5829 million yuan for the year 2024.
Gelonghui, February 27, Beijing Hotgen Biotech Co.,Ltd (688068.SH) announced its performance report for the year 2024. During the reporting period, the company achieved a total operating revenue of 1,806.3115 million yuan, a decrease of 9.96% year-on-year; the net income attributable to the parent company's owners was -86.5829 million yuan, a decrease of 199.92% year-on-year; the net income attributable to the parent company's owners after deducting non-recurring gains and losses was -106.2866 million yuan, a decrease of 232.18% year-on-year.
Beijing Hotgen Biotech Co., Ltd (688068.SH): plans to carry out a non-proportional capital reduction for Yujing Pharmaceuticals together with Lin Changqing and Yaojing Partners.
On February 17, Gelonghui reported that Beijing Hotgen Biotech Co., Ltd (688068.SH) announced that it convened the 26th meeting of the third Board of Directors on February 14, 2025, to review and approve the proposal regarding the reduction of capital and related transactions of its holding subsidiary. Beijing Hotgen plans to conduct a non-proportional capital reduction for its holding subsidiary Yujing Pharmaceutical with Mr. Lin Changqing and Yaojing Partnership, reducing the registered capital by a total of 20 million yuan. After this capital reduction is completed, Yujing Pharmaceutical's capital will decrease from the original 50 million yuan to 30 million yuan. The company holds 58% equity in Yujing Pharmaceutical, which remains a holding subsidiary of the company.
Beijing Hotgen Biotech Co.,Ltd (688068.SH): has cumulatively repurchased 0.93% of its shares.
On February 6, Gelonghui reported that Beijing Hotgen Biotech Co., Ltd (688068.SH) announced that as of January 31, 2025, the company repurchased 860,500 shares through the trading system of the Shanghai Stock Exchange via centralized bidding, accounting for 0.93% of the company's total share capital of 92,474,692 shares. The highest price of the repurchase was 80.80 yuan/share, the lowest price was 67.29 yuan/share, and the total funds paid amounted to 63,443,433.17 yuan (excluding stamp duty, transaction commissions, and other transaction fees).
The clinical trial application for the innovative drug AA001 monoclonal antibody developed by a subsidiary of Beijing Hotgen Biotech Co.,Ltd has been approved.
Beijing Hotgen Biotech Co.,Ltd (688068.SH) announced that the company's equity holding in Shenzhen Zhiyuan Biomedical Co., Ltd. (abbreviated...)
